Anabolic steroids are derivatives of testosterone that were developed in an attempt to dissociate the androgenic and anabolic effects of testosterone so that only the anabolic effects were maintained 3),60,105, &dquo;)' and the androgenic side effects were minimized. As yet, it has been impossible to completely dissociate the twO.3').60 l05 Anabolic steroids have two widely acceptable medical uses: because of their ability to stimulate erythropoiesis,35,62, 105 they are used in the treatment of certain types of anemia; they are also useful in stimulating sexual development in hypogonadal males.3,). 10') Anabolic steroids can be categorized broadly into those that are active when taken orally and those that are active when given parenterally ( Table 1 ). Most of the orally active steroids are produced by adding an alkyl group at C-17 of the D-ring in the basic testosterone nucleus.35.l05.108 The parenterally active anabolic steroids are two esters of 19nortestosterone-nandrolone decanoate and nandrolone phenpropionate. Both are given intramuscularly. 31,101 Testosterone itself is not really an anabolic steroid because it retains its full androgenic effect; it is best described as an androgenic/anabolic steroid.105 Esters of testosterone, which are long-acting preparations,&dquo;, '0' are testosterone propionate, testosterone enanthate, and testosterone cypionate.
drug testing techniques. 112
The use of anabolic steroids by athletes is quite controversial. The first major area of controversy is whether the steroids do, indeed, improve athletic performance. Many athletes having personal experience with these steroids insist that their performance is improved,&dquo; 32,45°ss while the medical and scientific communities doubt the effect of steroids, citing the inconsistencies of studies on the effects of steroids on athletic performance, with a large number demonstrating no improvement.2 The second major area of controversy is whether anabolic steroids are harmful to the athletes. Many of the athletes who have taken or are taking steroids believe that the side effects are not serious or permanent. 63.83,99 On the other hand, the medical and scientific communities point to reports of abnormal liver function tests, changes in the reproductive system, peliosis hepatis, and liver tumors as being indicative of their deleterious effects in chronic users of anabolic steroids.2
The result of this credibility and information gap between the athletes and the medical community is the present banning of the use of anabolic steroids by athletic organizations24, 68. 83, 99,112 to protect the athletes from potentially harmful side effects.105 To enforce these bans, detection procedures have had to be developed, 5,16,42,83,105 since athletes continue to use the drugs despite both the bans and the warnings of the medical community.99,lOO,105 Even though testosterone has its full androgenic effect, it reportedly is being used more frequently by athletes because it is more difficult to detect than other preparations.16.42. 83 In this paper, we specifically address the question of whether anabolic steroids do enhance athletic performance by testing the hypothesis that the inconsistencies in the findings of studies on the effects of anabolic steroids on athletic performance are the result of differences in the protocols of the various studies. We address the question of whether anabolic steroids are harmful by carefully analyzing Generic and trade names of anabolic steroids in common use all of the reported cases of subjective side effects, peliosis hepatis, and liver tumors, and by carefully analyzing all studies investigating the effects of anabolic steroids on liver function tests and on the reproductive system in humans.
The result of this detailed review is a concise summary of the literature on anabolic steroids, a summary that we believe can help to close the credibility and information gap between the athletes who feel the need to use anabolic steroids and the medical and scientific community who fear the deleterious effects of those steroids.
THE EFFECTS OF ANABOLIC STEROIDS ON ATHLETIC PERFORMANCE Methods
Twenty-five well-documented studies on the effects of anabolic steroids on athletic performance were found in the literature. Fourteen of these studies investigated the effects on human strength;6.8.l9.2'3.1l.12.34.47. 7'). 76.85.89,96,100 one study investigated the effects on human aerobic performance, 74 and ten studies investigated the effects on both human strength and aerobic performance. 14.26.46. ')2-54, 65, 77, 94, 106 Of the studies investigating the effects on aerobic performance, ten found no change in either performance times or maximal oxygen uptake.14.26,46.52.54. 65, 74, 77, 94, 106 One study did find improvement in maximal oxygen uptake,53 but this same author did not find such an improvement when he repeated his study. 12 Therefore, the literature is quite consistent in reporting no improvement in the aerobic performance of athletes treated with anabolic steroids.
The findings of those studies investigating the effects of anabolic steroids on human strength were not so consistent. Fourteen of these studies reported significant strength increases with steroids.6.8, 14.12.47,')2. ')1. 75-77.89 .96,100, 106 Ten reported no increase in strength.19.21.26.11.34.46.')4,6'). 85 .94 There- fore, our investigation of the inconsistencies in the literature on anabolic steroid effects on athletic performance was concentrated on the effects on human strength. Since 1 of the 25 studies of athletic performance included a study of only aerobic performance, 74 that study was not included in our analysis of variables. In addition, 1 of the 24 remaining studies investigated both changes in aerobic performance in a population of competitive swimmers and changes in strength in a population of competitive weight lifters.&dquo; Only the latter part of the study was used in our analysis.
To test the hypothesis that the different effects on human strength that have been reported for anabolic steroids were due to differences in study protocols, we distilled all of the studies investigating those effects into variables describing the protocols and the results of the studies (Table 2) . We then analyzed those variables to determine if any were consistently associated with either significant increases or absence of increases in strength during steroid treatment.
We tested the statistical significance of the association Variables analyzed to assess the effect of anabolic steroids on athletic performance between the number of studies containing any of those variables and whether those studies reported strength increases or no strength increases. The statistical significance of these associations was determined by the Fisher exact test.38
Results
Tables 3 and 4 summarize the variables for each of the 24 studies in relation to whether human strength was signifi-cantly increased (Table 3) or not significantly increased (Table 4 ) with the use of anabolic steroids.
The variables of weight lifting training before and during steroid intake and protein supplement intake are summarized in Table 5 . The association between studies using athletes trained in weight lifting before starting a regimen of anabolic steroids and the finding of significant increases in strength was statistically significant, as was the association between studies not using athletes trained in weight   TABLE 3 Studies finding significant increases in strength' with the use of anabolic steroids° As compared to control or placebo &dquo;Experienced in weight lifting beyond the mtroductory level of at least several months' duration c N, no, Y, yes d -imphes no mention of variable within the study ' C, controlled, NB, not blmd, NC, not controlled, DB, double blmd, SB, single blind; CO, crossover.
1-RM, maximal weight for single repetition of an exercise, BP, bench press, SQ, squat, PR, overhead press; OL, olympic lifts; CU, two-arm curl, DL, dead lift 8 Y or N implies that all of the athletes treated with steroids did or did not, respectively, demonstrate those changes &dquo; Does not include eight competitive swimmers whose swim times were studied independently of the three subjects listed here ' Force expiratory volume over 1 second Studies reporting no significant increases in strength&dquo; with the use of anabolic steroids° As compared to control or placebo. b Experienced m weight lifting beyond the mtroductory level of at least several months' duration. ' N, no; Y, yes d -implies no mention of variable within the study e C, controlled, NB, not blmd; NC, not controlled, DB, double blind, SB, smgle blmd, CO, crossover f 1-RM, maximal weight for single repetition of an exercise; BP, bench press, SQ, squat, PR, overhead press; DL, dead lift; CU, two-arm curl. e Y or N implies that all of the athletes treated with steroids did or did not, respectively, demonstrate those changes lifting before starting a regimen of steroids and the finding of insignificant increases in strength. However, since all athletes who are trained in weight lifting before steroid treatment continued their weight lifting training during the steroid regimen, these two variables were not independent of each other and were therefore considered together in our analysis. Thus, it was the combination of being previously trained in weight lifting and of continuous training in weight lifting during the steroid regimen that was consistently associated with significant increases in strength. Those stud-ies using athletes not previously trained in weight lifting were equally distributed into those where the athletes continued weight training during the steroid regimen and those where they did not. Therefore, in this group, these two variables were apparently independent of each other and could be considered separately in our analysis. Weight training during steroid intake as a variable by itself did not correlate with either set of results, nor did a high-protein diet in the 21 studies that specifically mentioned the athletes' diets. However, we speculate that since the three Experimental design in anabolic steroid studies studies that reported significant increases in strength but did not document the diets of the athletes6.8 47 had all used experienced weight lifters, those athletes were most likely on self-imposed protein-enriched diets because of their interests in body health and development. On the other hand, there were no studies without significant strength increases that did not mention diet. Therefore, the lack of dietary history in three of the studies may have skewed our data on the association between high-protein diet and changes in human strength. Table 6 describes the protocols of the studies on human strength. Even though none of the associations between the variables and the results of the studies were statistically significant, some of the findings were interesting. While all ten of the studies without significant increases in strength were controlled, 1 of the 14 studies with increases in strength was not. That study, by O'Shea and Winkler, was published in 1970 and investigated the effects of steroids on three weight lifters of championship caliber.&dquo; Because of that level of expertise, the authors felt that a comparable control group was unavailable.
All but one of the studies that did not find significant strength increases were double-blind studies and only one study was single-blind.&dquo; On the other hand, seven of the 14 studies that demonstrated significant strength increases were double-blind,6.8.12.47..,)2. 7'). 106 four were singleblind, 14,76,89,100 and three were unblinded studies. 1'3,77,96 One of the three studies that did not employ a blind protocol was the study by O'Shea and Winkler described above.&dquo; As indicated, they did not feel that enough subjects of the same caliber were available for a blind study. The second study that did not employ a blind protocol was by Tahmindjis.96
That author gave no indication why he did not use a blind protocol, but it can be surmised that, since his study investigated amateur weight lifters who had come to him requesting anabolic steroids, he may have felt obligated to give steroids to all of the athletes. The third study, by Johnson and O'Shea, was not blind because publicity about the adverse side effects of anabolic steroids made it difficult for them to find enough subjects willing to take the steroids for experimental purposes.53
The same problem was encountered by Stamford and Moffatt,89 and was given as the reason their study was a single-blind rather than a double-blind study. No explanation was given by the authors of the other four single-blind studies. Table 7 demonstrates that the type of strength measurement technique used in a study correlated with the results of the study at a statistically significant level. The technique of measuring the maximal weight lifted in a single repetition of a weight lifting exercise (1-RM) was employed by nearly all of the studies with significant strength increases. The use of strength measurement techniques exclusive of the 1- In all 14 studies reporting significant increases in strength, the orally active anabolic steroids, and almost exclusively methandrostenolone, (Dianabol) had been used (Table 8 ). The association of the studies using methandrostenolone with the findings of significant increases in strength was statistically significant, as was the association of studies using anabolic steroids other than methandrostenolone with the findings of insignificant increases in strength. The anabolic steroid dosage and the medication period were similar in all studies regardless of whether increases in strength were reported or not. All &dquo;athletic&dquo; variables that were studied in addition to strength are shown in Table 9 . Among the nine studies on human strength in which cardiorespiratory function and aerobic performance were also studied, 14,26 46 ')2-')4 6~ 94.106 four demonstrated significant increases in strength when steroids were used, 14 52,53,106 but only the study by Johnson and O'Shea53 in 1969 demonstrated a significant improvement in cardiorespiratory function with the administration of anabolic steroids. Using the same protocol in a study in 1971, Johnson et al. 52 failed to duplicate their findings. O'Shea investigated the effects of anabolic steroids on the aerobic performance of athletes in one study, 74 and the effects on human strength as well in a second study.&dquo; In both of these studies, no improvement in the aerobic performance or in the cardiorespiratory function of the athletes was found. Therefore, studies both with and without significant increases in strength consistently failed to document significant improvement in cardiorespiratory function or aerobic performance following administration of anabolic steroids to athletes. Table 9 also shows that the association between studies reporting increased body size and increased body weight and the findings of significant strength increases was statistically significant, as was the association between studies reporting no changes in body size or body weight and the findings of insignificant strength increases. Although increased lean body weight appeared to be associated with significant strength increases, this association lacked statistical significance because of the low numbers involved.
Discussion
Our review supports the observations of several authors that subjects trained in weight lifting prior to being treated with anabolic steroids and who continue training during treatment seem consistently to increase their strength over what would have been expected from training alone.26.32.52.62,63.66.77.107 Our review likewise supports the observations of these same authors that subjects not previously trained in weight lifting prior to steroid treatment do not seem to increase their strength significantly while training during the steroid regimen. However, our review did not support the contention of several authors that severe muscle stress through weight lifting must be concomitant with highprotein intake in order for anabolic steroids to have a demonstrable effect on human strength.26,32,52.62, 77 However, as mentioned earlier, our analysis of that association may have been distorted by the lack of sufficient dietary records in several studies. To understand why anabolic steroids seem to increase strength only in athletes who are previously trained in weight lifting and who continue weight lifting during the steroid treatment, we must now look at the mechanisms of action of these drugs.
In combination with their anabolic effects in athletes, anabolic steroids have both anticatabolic and motivational effects. The anticatabolic effects, which many authors believe to be the most important effects, 17,26,6' are mediated in two ways: anabolic steroids can reverse the catabolic effects of glucocorticosteroids that are released during periods of stress, 10,17,60,97 and they can convert a negative nitrogen balance to a positive balance by improving the utilization of ingested protein, thereby increasing nitrogen retention.35, so This effect is contingent upon adequate protein intake, since it has been noted that anabolic steroids may fail to induce significant nitrogen retention in a diet deficient in calories and protein .35,60 The quality of the ingested protein is also important. A deficiency in any of the essential amino acids will diminish but not totally abolish the increased nitrogen retention .60 The net effect of these two responses is to reverse the catabolic state in any subject who undergoes significant stress (such as athletic endeavor) or who is in negative nitrogen balance. Although the reversal of the catabolic effects of glucocorticosteroids seems to continue as long as the anabolic steroid treatment continues, the induced positive nitrogen balance will eventually return to equilibrium as a result of the homeostatic mechanisms that work to maintain nitrogen equilibrium in the normal state.60. 105,107
In the normal, healthy state, the anticatabolic effects of anabolic steroids do not come into play, and the anabolic effects are nominal and short-lived. The anabolic effects under these circumstances are mediated in two ways. One, the anabolic steroids will shift nitrogen equilibrium to a positive nitrogen balance as a result of increased nitrogen retention through improved utilization of ingested protein, again assuming that the protein intake is adequate.35.60
However, the body's homeostatic mechanisms work to return the positive balance to a state of nitrogen equilibrium, and the positive nitrogen balance is thus only short-lived. Exactly how long the nitrogen balance remains positive in a normal, healthy adult is not known, but it is much shorter than that induced in a catabolic state.60.IO,).107 The second anabolic effect of anabolic steroids is the ability to induce protein synthesis in skeletal muscle cells. Cytoplasmic receptors for anabolic steroids have been found to exist on muscle cells.35.61,82 Through these receptors, anabolic steroids activate the synthesis of ribosomal and messenger RNA, and thereby initiate the process of protein synthesis within the skeletal muscle cells .11,60, &dquo; This anabolic effect continues indefinitely during steroid treatment and occurs in both the healthy and the catabolic state.
Finally, the motivational effects of anabolic steroids have been well-documented. Athletes taking anabolic steroids experience a state of euphoria and diminished fatigue, which enhances training. 32.4').61.66.10') This effect is maintained as long as the athlete takes the steroids. Anabolic steroids also have a profound psychological effect on the athlete and thus provide a placebo effect, as has been demonstrated by Ariel and Saville.~ In their study, they found that when experienced weight lifters who were actually receiving a placebo were told that they were receiving the anabolic steroid methandrostenolone, they demonstrated statistically significant improvements in their weight lifting exercises when compared to the pre-placebo period. Taking the placebo and thinking that it was an anabolic steroid supplied the necessary psychological motivation for the athletes to increase their strength over what would have been expected in the absence of an anabolic steroid.
Intense weight lifting can force an athlete into a catabolic state, first by stressing the body and thus causing the release of glucocorticosteroids 6' and second by substantially increasing nitrogen utilization. The heavily trained weight lifter needs to ingest 2.0 to 2.2 gm of protein per kilogram of body weight daily just to maintain nitrogen balance; with less, he will suffer a negative nitrogen balance .20 That amount of protein is considerable and is not easily maintained ; thus many weight lifters are in negative nitrogen balance. As a result of the catabolic effects of glucocorticosteroids and the negative nitrogen balance, intensively trained weight lifters are often in a chronic catabolic state. This may be why many weight lifters reach a plateau in their development. Since anabolic steroids are profoundly anticatabolic, they would be expected to have dramatic effects on athletes who are in a chronic catabolic state.
When they are given to athletes who are in a mildly negative nitrogen balance, they would allow better utilization of the ingested protein with a resultant positive nitrogen balance. The steroids would also help to reverse the catabolic effect of glucocorticosteroids released during stressful training. As a result, the intensively trained weight lifter would be expected to realize increased strength with steroids over what training without steroids would allow, assuming that his diet was adequate in protein and calories and assuming that he maintained his training during the steroid treatment. On the other hand, an athlete not trained in weight lifting prior to anabolic steroid treatment would not be expected to be in a catabolic state or in a negative nitrogen balance; anabolic steroids would be expected to cause only a short-lived transient shift to a positive nitrogen balance; and, since the other anticatabolic effects would not be at work, the net effects of the steroids in this athlete would be nominal.
The results of our review are consistent with what the proposed mechanisms of action of anabolic steroids would predict as far as previous training is concerned. Our analysis of the mechanism of anabolic steroids suggests that a highprotein diet may be more significant to the effects of the steroids than our review suggests, but our data on this effect suffer from the lack of a dietary history in three of the studies reviewed.
Several of the studies demonstrating significant strength increases with anabolic steroids have been criticized because they did not employ a double-blind protocol in their experimental procedure.23,75.83.94.107 As noted in the previous section of this paper, only 7 of the 14 studies with significant increases in strength employed a double-blind protocol; 9 of the 10 studies that did not demonstrate significant strength increases employed a double-blind protocol. The use of a double-blind protocol would seem to be very important when studying the effects of anabolic steroids on athletes since it has been demonstrated by Ariel and Saville9 that a placebo effect can occur in studies of anabolic steroids. The doubleblind protocol would minimize the placebo effect by preventing either the subjects or the investigators from knowing whether a drug or a placebo was being used. However, it has been demonstated that some athletes studied were able to differentiate placebo from anabolic steroid during doubleblind administration, thus unmasking the double-blind protocol. For example, in a study by Crist and associates in 1983,21 nine weight lifters were involved in a double-blind crossover study and were treated on a rotating basis with injectable placebo, nandrolone decanoate, or testosterone cypionate, with the order being known neither by the athletes nor by the investigators. Based upon a feeling of &dquo;increased strength,&dquo; the athletes were able to differentiate steroid treatment from placebo treatment. This finding was statistically significant. Interestingly, those same athletes showed no significant increases in strength when they were tested objectively. Similarly, Freed and associates in 197532 investigated 13 weight lifters in a double-blind crossover study. In that study, the weight lifters were treated with oral methandrostenolone and oral placebo in a sequence unknown to both the lifters and the investigators. All 13 subjects could predict their sequence of steroid and placebo treatment before the double-blind protocol was decoded. In this study, the investigators did find a significant increase in strength in the athletes who have been given anabolic steroids. Therefore, it appears that athletes can differentiate steroid from placebo treatment even when a double-blind protocol is used. This makes the use of double-blind protocols insignificant when investigating the effects of anabolic steroids on human performance.62. 61
Methandrostenolone (Dianabol) was the first anabolic steroid used by many of the athletes who have experimented with these drugs and is probably still the most popular anabolic steroid known to athletes.9l,108 There are no significant pharmacologic differences between it and the other orally active C-17 alkyl derivatives of testosterone that would render it a more potent anabolic agent.3,) It may be that the popularity of Dianabol among weight lifters resulted in it being used more frequently when this population was studied. As we have pointed, out, it is this population that consistently demonstrated significant strength increases with the use of anabolic steroids. Therefore, the association of methandrostenolone with strength increases may be an incidental finding.
The statistically significant association between those studies using the 1-RM technique for strength measurement and significant strength increases suggest that the 1-RM technique may be a more sensitive measurement technique than the other techniques mentioned in Table 7 . This suggestion is further supported by a study by Hervey and associates,&dquo; who demonstrated significantly increased strength during anabolic steroid treatment with the 1-RM technique but not with dynamometer measurements in the same athletes. Other authors have noted that there are limitations in the use of single-joint isolation-testing techniques, such as Cybex machines and dynamometers, to assess the muscular power gains made from multiple-joint weight lifting exercises.&dquo; Since the 1-RM method uses the same exercises and movements that are being used during weight lifting training, e.g., bench press and squat, it seems likely that this technique would more accurately reflect gains in strength than a testing technique that employs movements and exercises in which the athlete is not trained.
Seven of the ten studies that did not demonstrate significant strength increases did not use the 1-RM technique.19.23 31, 46, 54, 85 94 Had the 1-RM technique been used in those studies, more significant changes in strength might have been demonstrated.
It has been suggested that the increase in total body weight, body size, and lean body weight reported in some athletes taking anabolic steroids are the result of mechanisms such as fluid retention and not the result of increases in muscle mass.19.32,46,61 However, our review demonstrates statistically significant associations between studies reporting increases in body size and body weight and the findings of significant increases in strength. Our review also demonstrates a statistically significant association between those studies reporting no increases in body size and body weight and the findings of no significant increases in strength. These findings suggest that the increases in body size and body weight were the result of increased muscle mass.
A total of ten studies~-~-~-~.~100 were of athletes (1) who were trained in weight lifting prior to anabolic steroid treatment and who continued weight lift training during steroid treatment, (2) who used the anabolic steroid methandrostenolone, and (3) whose strength was measured by the 1-RM strength measurement technique. Nine of those ten studies demonstrated significant strength increases with anabolic steroids.
A total of five studies'9,31,54,85,11 were of athletes (1) who were not previously trained in weight lifting, (2) who used steroids other than methandrostenolone, and (3) whose strength was not measured by the 1-RM strength measurement technique. All five of those studies found no changes in strength with anabolic steroids.
Therefore, our analysis of the literature on the effects of anabolic steroids on human strength supports the hypothesis that the inconsistencies found in the literature are the result of inconsistencies in the protocols of the studies; studies with consistent protocols yielded consistent results.
THE SIDE EFFECTS OF ANABOLIC STEROIDS
This part of the review was designed to assess the side effects of anabolic steroids and included studies of both athletes and nonathletes.
Methods
Subjective side effects. We defined &dquo;subjective side effects&dquo; as those that an athlete claimed to have had during the use of anabolic steroids. These effects cannot be measured.
A total of 13 studies investigating the subjective side effects of anabolic steroids were found in the litera-~1 103 We recorded the total number of athletes demonstrating altered liver function tests (LFTs) while taking anabolic steroids as well as a subtotal for each LFT, and analyzed the distribution of abnormal LFTs according to the anabolic steroid used.
We considered separately the nonspecific LFTs and the liver-specific LFTs. The nonspecific LFTs are enzymes found in the liver as well as in other organs: serum glutamicoxalacetic transaminase (SGOT), which occurs in significant concentrations in the liver, heart, skeletal muscle, kidney, and pancreas; serum glutamic-pyruvic transaminase (SGPT), which is found in the liver, kidney, heart, and skeletal muscle; and lactic dehydrogenase (LDH), which is present in high concentrations in the liver, heart, skeletal muscle, and erythrocytes. 112 Separation of the isoenzymes of LDH by electrophoretic, chromatographic, and immunologic characteristics produces a liver-specific isoenzyme of LDH that can be used as a liver-specific LFT.102 Alkaline phos-phatase concentration has been demonstrated in the liver, bone, placenta, and intestine, but circulating alkaline phosphatase derives primarily from bone and liver in adults.102 Since neither athletic activities nor anabolic steroids significantly stimulate the osteoblastic activity that is associated with elevated serum alkaline phosphatase from bone, we considered alkaline phosphatase to be a liver-specific LFT in our review. Therefore, we considered both alkaline phosphatase and the liver isoenzyme of LDH to be liverspecific LFTs. We considered elevation of either of these enzymes in the presence of athletic activity or anabolic steroid treatment to be secondary to hepatocellular dysfunction.
Reproductive system effects. Nine studies investigated the effects of anabolic steroids on the reproductive systems of 77 athletes.~~-~-~'~ We recorded the number who demonstrated a change in testosterone levels, gonadotropin levels, or spermatogenesis during anabolic steroid treatment.
Severe hepatic side effects. Both malignant and benign liver tumors and peliosis hepatis have been reported to occur in conjunction with the use of anabolic steroids. Peliosis hepatis is a rare form of hepatitis, historically associated with tuberculosis.11° It is characterized by the formation of multiple, small, blood-filled, cystic lesions within the liver. A prerequisite for peliosis hepatis is believed to be disseminated foci of hepatic necrosis that eventually form hemorrhagic cystS.11. 110 We reviewed reports of 23 cases bn is total number of athletes with at least one subjective side effect from population N. c Exact number not given by the study. Correlation of subjective side effects in athletes and specific anabolic steroids'° Does not include 29 athletes (of the total 155 tested) whose anabolic steroids were not identified. b First number is total number of athletes experiencing side effects with the use of the anabolic steroid; number in parentheses is total number of athletes receiving that steroid.
c Only one study used this steroid.
TABLE 12
Abnormal liver function tests (LFT) in athletes associated with anabolic steroids (N = 149) a a N is total number of athletes evaluated for abnormal liver function tests in all studies.° n is total number of athletes having abnormal LFTs. ' One athlete also had a normal alkaline phosphatase and three athletes had a normal SGPT. d Twenty-nine athletes also had a normal alkaline phosphatase. e All 11 athletes had a normal SGOT.
Results
Subjective side effects. Of the 155 athletes studied in the 13 investigations of subjective side effects during the administration of an anabolic steroid, 52 reported such effects (Table 10 ). All athletes reported reversal of the side effects when the anabolic steroid was discontinued. Methandrostenolone was the anabolic steroid used most frequently by the 155 athletes,32.47.52.53.75,8S,89,96 and 25% of those using methandrostenolone reported subjective side effects (Table   11 ). All 11 athletes taking oxandrolone in one study&dquo; had subjective side effects, but none of the athletes taking stanozolol in another study reported such effects.19 Liver function tests. LFTs were abnormal in 70 of 149 athletes, all of whom were taking oral steroids. Two of the 11 studies of athletes summarized in Table 12 investigated the effects of weight lifting with and without the administration of anabolic steroids on LFTs.41.91 In the study by Strauss and associates9l of 32 weight lifters, the 20 using oral anabolic steroids had SGOT values at the upper levels of normal and SGPT levels of greater than normal values; the 12 not using anabolic steroids had SGOT and SGPT values almost identical to those taking steroids; and a control group of seven subjects involved in a low-intensity weight lifting program for general conditioning had normal SGOT and SGPT values. Hagerman and associates4l studied five weight lifters, three treated and two not treated with anabolic steroids. All five had elevated SGOT and LDH values, but they also had normal SGPT and alkaline phosphatase levels. These two studies demonstrated that intense weight lifting, by itself, can elevate the nonspecific LFTs. On the other hand, nonspecific LFTs can also be elevated by anabolic steroid treatment in the absence of intense exercise, as was demonstrated in the study by Westaby and associates in 1977.103 These investigators studied the LFTs of 42 female transsexuals and 18 impotent males being treated with longterm methyltestosterone to maintain secondary male sexual characteristics. In their investigation, 19 of the 60 nonathletes had elevated SGOT values and 33 of 52 subjects had abnormal liver scans.
As can be seen in Table 12 , the majority of the athletes had elevated nonspecific LFTs&dquo;-&dquo;'&dquo; 74.88.91; a much smaller number had elevated liver-specific LFT. 17, All of the subjects studied, except for 19 competitive swimmers, were involved in intense weight training. Eight of the 19 heavily trained swimmers had elevated LDH liver isoenzyme levels&dquo; and 11 had elevated SGOT levels while taking anabolic steroids. 74 As indicated in the footnotes of Table 12 , several of the athletes demonstrating elevated nonspecific LFT values had normal alkaline phosphatase levels,', 9' a finding that suggests that the elevation in LFT values may have been secondary to the breakdown of skeletal muscle rather than to hepatocellular dysfunction. Conversely, all of the athletes in the study of O'Shea and Winkler&dquo; demonstrated elevation of the LDH liver isoenzyme but had normal SGOT values, findings that suggest that hepatocellular dysfunction was the cause of the elevated LFT values in that study. Table 13 correlates abnormal LFTs with specific anabolic steroids. Only two of the athletes using methandrostenolone had abnormal liver-specific LFT values&dquo;; all 11 athletes taking oxandrolone in one study had abnormal liver-specific LFTs.&dquo; Only Freed and associates&dquo; mentioned the effects of discontinuing anabolic steroids on LFTs that had been elevated during steroid use. In that study, only one patient had an abnormally elevated SGPT during steroid administration, and this returned to normal when the steroid was discontinued.
Reproductive system effects. Table 14 summarizes nine studies that investigated the effects of anabolic steroids on Table 14 , studies that reported changes in go-nadotropins26,46.8l.94 did not differ markedly in either the dose of the steroid used or the duration of the treatment from those that did not report such changes.
Stromme and associates', 94 determined that it was the &dquo;protein-bound fraction&dquo; of testosterone that decreased during the administration of the anabolic steroid; the amount of free-plasma testosterone remained unchanged. Remes and associates&dquo; found that decreased plasma testosterone in 12 athletes had returned to normal 10 days after the anabolic steroid was discontinued, but, 2 to 6 weeks later, the plasma testosterone levels seemed to overcompensate with values that were elevated over baseline values. In that same study, the ICSH and FSH levels, although not changed during anabolic steroid administration, did decrease when plasma testosterone became elevated following discontinuance of the steroid. In the study of Clerico and associates,21 the FSH and ICSH levels that were decreased during steroid administration had returned to normal levels 7 days following discontinuance of the steroid, but the decreased plasma testosterone levels had not returned to normal at that time.
Of the two studies investigating the effects of anabolic steroids on the sperm count in athletes, 41 52 only one, that by Holma,49 in which 15 athletes had been given 15 mg of methandrostenolone daily for 2 months, showed a change in sperm count. In that study, the sperm count had decreased an average of 73% over 2 months of anabolic steroid treatment in the 15 athletes studied. Three of the subjects had become azoospermic; the percentage of motile cells had decreased by 30%; the percentage of spermatozoa with normal configuration had decreased from 73 to 42%; and the percentage of spermatozoa with amorphous heads had increased by 100% during the 2-month treatment period. The authors also used a &dquo;fertility index,&dquo; originally described by Eliasson 2' to evaluate the specimens of each athlete. Only one subject's fertility index remained normal during the treatment period, four had doubtful indices, three had pathologic indices, and seven had severely pathologic indices at the end of the study. Three months after discontinuance of the anabolic steroid, sperm density, sperm motility, and sperm morphology had completely recovered.
In the other study investigating sperm count with anabolic steroids, Johnson and associates52 found no changes in the athletes who had been given 10 mg of methandrostenolone daily for only 3 weeks. The differences in the anabolic steroid dose and duration of treatment may explain why Holma Peliosis hepatis. Twenty-three reported cases of peliosis hepatis associated with the use of anabolic steroids that have been reported in the literature are summarized in Table  15 . All 23 patients were being treated with anabolic steroids for medical illnesses. Most of the patients suffered from some form of anemia or pancytopeniall 19')761 68.7271.101; I there have been no cases of peliosis hepatis reported in athletes or otherwise healthy subjects. Twenty-two of the 23 patients had been treated with the orally active C-17 alpha alkyl derivatives of testosterone. The 23rd patients was treated with an injectable anabolic steroid, testosterone enanthate, which is an ester of testosterone. As such, it is not truly an anabolic steroid, but rather an androgenic/ anabolic steroid, since it retains the full androgenic effects of testosterone. Table 15 shows that all 23 patients had been treated for prolonged periods, only four of them having been treated for less than 6 months. 11.72 Liver tumors. Thirty-six cases of liver tumors associated with the use of anabolic steroids have been reported: one was in an athlete, 71 the rest were in patients being treated for medical illnesses. The majority of the tumors were mal. ~ 12,15,22,27 2s, 30, '16, 40 43 48,51 55 57 69, 70 78 80,84,86 87,93,111 Eight of the tumors were associated with peliosis hepatis (Table  16 ).~~ ~~. ~~ ~~ s4,s9 so 84 87 Five of the reported hepatocellular carcinomas and one of the reported hepatic adenomas improved once the anabolic steroids were discontinued.30 51 71, ss, a7 As in the case of peliosis hepatis, all but one of reported cases of liver tumors were associated with the use of orally active C-17 alpha alkyl derivatives of testosterone. And, as in the case of peliosis hepatis, the one liver tumor reported to be associated with the exclusive use of an injectable anabolic steroid was in a patient treated with testosterone enanthate, an androgenic/anabolic steroid.&dquo; Finally, as in the case of the patients with peliosis hepatis, the patients in whom liver tumors were reported had been treated with anabolic steroids for long periods of time, only four having been treated for less than 6 months and 23 having been treated for more than 2 years. Oxymetholone was the most frequently used anabolic steroid in reported cases of both peliosis hepatis and liver tumors.
The one case of a liver tumor in an athlete associated with steroid use was in a male body builder who died of hepatocellular carcinoma and hepatic cholangiocarcinoma.78 The athlete had used multiple oral and injectable anabolic steroids for the 4 years before his death, including methandrostenolone, oxandrolone, stanozolol, and methenolone by mouth, and nandrolone decanoate intramuscularly. This patient had had no previous liver disease, but his other past medical history was not given. As in the case of almost all of the other reported patients with liver tumors associated with anabolic steroids, this athlete had used orally active C-17 alpha alkyl testosterone derivatives for a prolonged period of time.
Discussion
Subjective side effects. Although most of the side effects listed in Table 11 have been documented as occurring with anabolic steroids, their relative frequency has never been clearly documented. Over 30% of the athletes questioned reported subjective side effects, all of which disappeared when the anabolic steroid was discontinued. Since only male athletes were investigated in these studies, we have no data on the side effects in children and women. It has been reported, however, that women may experience hirsutism, deepening of the voice, baldness, and clitoral enlargement, Summary of clinical data on peliosis hepatis associated with anabolic steroids (N = 23)°° N = number of cases reported, with the exclusion of eight cases reported in association with liver tumors. b All oral steroids were C-17 alpha alkyl derivatives of testosterone.
C Includes one study using two different oral anabolic steroids in the same patient.
d Testosterone enanthate (I.M.), two patients. e Testosterone enanthate (I.M.). which may not be reversible.',&dquo; 61,10') In children, anabolic steroids may cause premature closure of the growth plates with resultant short stature, which is not reversible.3,1,).61
Liver function tests. The association of elevated LFTs and the use of anabolic steroids has been well-documented in the literature. 63, 83, 107, 112 This association was also apparent in our review, with nearly 50% of the subjects studied demonstrating values above the normal range. However, over 75% of the elevated values were in nonspecific LFTs, and may have been elevated by intense exercise alone. This strongly suggests that only liver-specific LFTs, such as the liver isoenzyme of LDH and alkaline phosphatase, should be used to monitor liver function in athletes taking anabolic steroids.
Lamb61 has referred to elevated LFT values as being reversible once the anabolic steroid is discontinued; the one study in our review that discussed this point (in one patient) supported this claim Reproductive system effects. Decreased plasma testosterone was common in athletes treated with anabolic steroids; 1-Methyl derivative of testosterone taken concomitantly with C-17 alpha alkyl testosterone derivative. an associated decrease in the gonadotropins ICSH and FSH was less common. The mechanism by which these changes occur seems to be a combination of both central and local effects. To cause the central effect, anabolic steroids would replace testosterone in the negative feedback system mediated by the pituitary and the hypothalamus, thereby suppressing gonadotropin release by the pituitary which, in turn, would decrease plasma testosterone formation by the interstitial cells of the testes.2l 8R While this mechanism explains decreased plasma testosterone associated with decreased gonadotropin level, it does not explain the more frequent occurrence of decreased plasma testosterone associated with normal gonadotropin levels. The mechanism most likely at work here would be a local effect at the level of the testosterone-binding globulin. 1 81 8894 The anabolic steroid could displace testosterone from the testosteronebinding globulin in a competitive fashion, or it might cause a decrease in the synthesis of the testosterone-binding globulin in the liver. In both cases, the effect would be to displace testosterone from the testosterone-binding globulin, thereby decreasing the protein-bound fraction of plasma testosterone. More than likely, both central and local effects contribute to the overall effect in the individual athlete. Decreased plasma testosterone associated with anabolic steroid use would explain the subjective side effects of altered libido reported by many of the athletes; associated decreases in gonadotropins would explain the alteration in spermatogenesis reported by Holma.49 Therefore, while it appears that anabolic steroids have profound effects on the reproductive systems in males, the effects disappear once the steroids are discontinued.21 81
Severe hepatic side effects. Eigfht of the 36 reported liver tumors that have occurred in conjunction with anabolic steroid treatment demonstrated associated findings of peliosis hepat1S.12 15 44 55 64 69 RO R4 87 In addition, the reported cases of liver tumors were associated with a longer duration of steroid treatment than were the cases of peliosis hepatis. This suggests that peliosis hepatis may be a pretumorous lesion that can become malignant with prolonged anabolic steroid treatment. This concept has been postulated by Paradinas and associates, 79 who suggested that parenchymal disturbances of peliosis might pave the way for nodular hepatocyte growth and eventually for neoplasia when the liver overstimulated by anabolic steroids. They further suggested that cysts and nodules could be partially explained by hyperplasia, perhaps associated with the anabolic effect of 17-alpha alkylated synthetic androgens. Sweeney and Evans9' have suggested that anabolic steroids may induce tumors through intermediate hyperplastic lesions. Thus, there may exist a continuum of effects on the liver as a result of continuous anabolic steroid treatment. This continuum would begin with widespread hepatic hyperplasia that could progress to cystic degeneration, then to peliosis hepatis, and finally to liver adenomas and hepatocellular carcinomas with continued steroid treatment. This continuum of liver effects is almost exclusively associated with the use of the orally active C-17 alpha alkyl derivatives of testosterone. Many authors have recognized that these orally active derivatives are apparently far more hepatotoxic than the injectable derivatives.&dquo; 56 90 101 105 108 In our review, only one case of peliosis hepatis and one case of liver hepatoma were associated with the exclusive use of injectable testosterone enanthate.11 &dquo; There were no reports of these lesions occurring with the exclusive use of the injectable anabolic steroids that are 19-nortestosterone derivatives of testosterone; these include nandrolone decanoate and nandrolone phenpropionate. Other authors have also suggested that the 19-nortestosterone derivatives are less hepatotoxic and therefore safer to use.~° 1()8
The reported regression of hepatocellular carcinoma following discontinuance of anabolic steroids has caused some authors to question whether these lesions are truly malignant.30.33,50.51, 71,86 87 Anthony has suggested that hepatocellular carcinoma, regardless of how well-differentiated, is relentlessly progressive and malignant. He added that spontaneous regression is exceedingly rare once malignant neoplasms become manifest, and knew of no case of proven cancer that had regressed following withdrawal of a known or putative causative agent.4 Shapiro and associates87 have suggested that new terminology is needed to describe hepatocellular carcinomas associated with the use of anabolic steroid therapy, since, although they resemble carcinoma histologically, their clinical behavior is sometimes benign. If there is indeed a continuum of progressively severe liver lesions associated with prolonged anabolic steroid use, the lesions reported to be hepatocellular carcinomas may instead have been severe forms of hyperplasia that could be considered premalignant. Discontinuance of the steroid would then result in their resolution, but continued anabolic steroid treatment would result in their becoming frankly malignant lesions.
The 1984 report by Overly and associates&dquo; of hepatocellular carcinoma and hepatic cholangiocarcinoma in an athlete is disturbing, since it is the first report of severe liver dysfunction due to anabolic steroids used for athlete purposes. This patient apparently had no history of liver disease but his other past medical history was not reported. It is significant that this athlete developed these liver lesions while taking the orally active C-17 alpha alkylated testosterone derivatives, a finding that further supports the premise that severe liver dysfunctions are primarily associated with the prolonged use of these orally active anabolic steroids, even in the seemingly healthy athlete.
SUMMARY
The use of anabolic steroids by athletes is controversial. On the one hand, many athletes believe that steroids improve athletic performance and thus provide an advantage to those who use them. On the other hand, the medical and scientific communities believe that inadequate scientific data exist to support the claim that anabolic steroids can improve athletic performance while overwhelming scientific data demonstrate their deleterious effects. Therefore, a large information and credibility gap concerning anabolic steroids exists between the athletes and the medical and scientific communities. We believe that this gap can be closed if both groups are better informed about anabolic steroids. We provide a detailed review of the literature on anabolic steroids that provides to the reader the information needed to make an informed decision on the relative risks and benefits of anabolic steroids to the athlete. This review supports the following conclusions:
The Effects of Anabolic Steroids on Athletic Performance
The articles reviewed consistently demonstrated no improvement due to anabolic steroids in aerobic athletic performance, as measured by maximal Oz uptake and running and swimming times.
-The effects of anabolic steroids on human strength were inconsistent in the articles reviewed, with 14 articles reporting significant increases in strength and 10 reporting no significant increases in strength.
-Our review supports the hypothesis that the differences in the effects of anabolic steroids on human strength are the result of differences in the study protocols.
-Those studies demonstrating significant increases in strength were consistent at a statistically significant level in the following characteristics:
1. They studied athletes trained in weight lifting before anabolic steroids were started and who continued weight lift training during the anabolic steroid regimen. 2. They more frequently studied the effects of the orally active anabolic steroid, methandrostenolone, than the effects of all other steroids combined.
3. They measured the athletes' strength by using the single repetition-maximal weight technique for various weight lifting exercises.
-The association of the anabolic steroid methandrostenolone with significant strength increases seems to be more the result of its popularity than its pharmacology. -A high-protein diet also appears to be associated with significant increases in strength during the anabolic steroid regimen, but this association could not be effectively studied statistically because of the lack of dietary history in several of the studies.
-Those studies that did not demonstrate significant increases in strength were consistent at a statistically significant level in the following characteristics: 1. They studied athletes not trained in weight lifting before anabolic steroids were started.
2. They frequently studied the effects of anabolic steroids other than methandrostenolone.
3. They measured the athletes' strength by using techniques other than the single repetition-maximal weight technique for various weight lifting exercises. -Our review supports the hypothesis that anabolic steroids have their most pronounced effects in those athletes who have trained to the point that they are in a chronic catabolic state.
-Therefore, our review suggests that anabolic steroids will consistently result in significant strength increases if all of the following are satisfied:
1. They are given to athletes who have been intensively trained in weight lifting immediately before the start of the steroid regimen and who continue this intensive weight lift training during the steroid regimen. 2. The athletes maintain a high-protein diet. 3. The changes in the athletes' strength are measured by the single repetition-maximal weight technique for those exercises with which the athlete trains.
-Studies demonstrating significant increases in body size and body weight during the anabolic steroid regimen were consistently those studies that demonstrated significant increases in strength. These consistencies were statistically significant.
. Studies that did not demonstrate significant increases in body size and body weight during the anabolic steroid regimen were consistently those studies that did not demonstrate significant increases in strength. These consistencies were statistically significant.
The Side Effects of Anabolic Steroids . More than 30% of the athletes questioned reported subjective side effects while taking anabolic steroids; those side effects disappeared following discontinuance of the steroids. The most frequently reported subjective side effects were changes in libido, increased aggressiveness, muscle spasm, and gynecomastia.
-Double-blind protocols may not be useful in studying the effects of anabolic steroids in athletes because the athletes appear to be able to differentiate anabolic steroid from placebo treatment on the basis of mood changes caused by the anabolic steroids.
. Abnormalities in routine liver function tests (SGOT, SGPT) were associated not only with the anabolic steroid regimen but also with intense weight lifting in the absence of anabolic steroids. For this reason, only alkaline phosphatase and the liver-specific isoenzyme of LDH should be used to measure hepatocellular dysfunction in weight lifters, since these are liver specific tests.
. Abnormalities in liver function tests associated with an anabolic steroid regimen were reversible following discontinuance of the steroids. 0 An anabolic steroid regimen was frequently associated with a decrease in the plasma levels of the protein-bound fraction of testosterone. There was also a less frequently associated decrease in the plasma levels of the gonadotropins FSH and ICSH. Both the decreases in the protein-bound fraction of testosterone and in the two gonadotropins appeared to be reversible once the steroids were discontinued. 0 An anabolic steroid regimen was associated with profound alterations in spermatogenesis that could result in transient infertility. These alterations appeared to be reversible following discontinuance of the steroids. 0 Peliosis hepatis has been reported in association with anabolic steroid treatment. This is a rare finding: we found 23 cases reported in the literature. All of these cases were in patients being treated with anabolic steroids for medical illnesses and who were treated almost exclusively with the orally active C-17 alpha alkyl testosterone derivatives for durations of usually longer than 6 months. o Liver tumors, both benign and malignant, have been reported in association with anabolic steroid treatment. These, too, are rare findings: we found 36 cases reported in the literature. All of these cases but one were in patients being treated with anabolic steroids for medical illnesses and who were treated almost exclusively with the orally active C-17 alpha alkyl testosterone derivatives for durations usually longer than 24 months.
· There has been one reported case of hepatocellular carcinoma in an athlete who had taken anabolic steroids for body development. This athlete had taken multiple anabolic steroids for 4 years before his death. Most of the steroids that he had taken were orally active C-17 alpha alkyl testosterone derivatives.
. It appears that orally active C-17 alpha alkyl testosterone derivatives are much more hepatotoxic than the injectable forms of anabolic steroids. The hepatotoxicity appears to be related to the duration of treatment.
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